Kenneth T. Mills Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock
Regenxbio Inc (NASDAQ:RGNX) insider Kenneth T. Mills sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $26.56, for a total value of $265,600.00. Following the sale, the insider now owns 238,530 shares of the company’s stock, valued at approximately $6,335,356.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Regenxbio Inc (NASDAQ RGNX) traded up $0.45 on Friday, hitting $27.55. The stock had a trading volume of 234,300 shares, compared to its average volume of 403,553. Regenxbio Inc has a fifty-two week low of $16.30 and a fifty-two week high of $36.45. The firm has a market cap of $844.04, a PE ratio of -10.20 and a beta of -1.30.
Several institutional investors and hedge funds have recently modified their holdings of the company. RTW Investments LP raised its holdings in shares of Regenxbio by 1.4% in the 4th quarter. RTW Investments LP now owns 1,561,210 shares of the biotechnology company’s stock worth $51,910,000 after buying an additional 22,205 shares in the last quarter. Perceptive Advisors LLC raised its holdings in shares of Regenxbio by 5.1% in the 3rd quarter. Perceptive Advisors LLC now owns 1,441,186 shares of the biotechnology company’s stock worth $47,487,000 after buying an additional 70,000 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Regenxbio by 3.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,270,327 shares of the biotechnology company’s stock worth $40,778,000 after buying an additional 43,492 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Regenxbio by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock worth $21,379,000 after buying an additional 100,944 shares in the last quarter. Finally, Citadel Advisors LLC increased its holdings in Regenxbio by 62.2% during the 4th quarter. Citadel Advisors LLC now owns 987,752 shares of the biotechnology company’s stock valued at $32,843,000 after purchasing an additional 378,612 shares in the last quarter. 66.85% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Kenneth T. Mills Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://theolympiareport.com/2018/02/23/kenneth-t-mills-sells-10000-shares-of-regenxbio-inc-rgnx-stock.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.